Thomas Richard Kassberg - 01 Mar 2024 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Reporting relationship: CBO & EVP
Issuer ticker: RARE
Reported as of: 01 Mar 2024
Net transaction value: -$69,062
SEC form: 4
Accepted by SEC: 05 Mar 2024, 20:19:45 UTC
Prior SEC filing: 24 Oct 2023
Next SEC filing: 12 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Karah Parschauer, attorney-in-fact

Key filing fact

Thomas Richard Kassberg filed Form 4 for Ultragenyx Pharmaceutical Inc. (RARE) on 05 Mar 2024.

Key facts

This page summarizes Thomas Richard Kassberg's Form 4 filing for Ultragenyx Pharmaceutical Inc. (RARE).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Mar 2024, 20:19.

Change

Previous filing in this sequence was filed on 24 Oct 2023.
Current net transaction value: -$69,062.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RARE transaction

Common Stock

Award

Transaction value: $0
Shares: +17,800
Change %: +7.2%
Price: $0.000000
Shares after: 264,660
Date: 01 Mar 2024
Ownership: Direct
Footnotes: F1

RARE transaction

Common Stock

Award

Transaction value: $0
Shares: +957
Change %: +0.36%
Price: $0.000000
Shares after: 265,617
Date: 01 Mar 2024
Ownership: Direct
Footnotes: F2

RARE transaction

Common Stock

Tax liability

Transaction value: $14,711
Shares: -274
Change %: -0.1%
Price: $53.69
Shares after: 265,343
Date: 01 Mar 2024
Ownership: Direct
Footnotes: F3

RARE transaction

Common Stock

Sale

Transaction value: $54,351
Shares: -1,011
Change %: -0.38%
Price: $53.76
Shares after: 264,332
Date: 01 Mar 2024
Ownership: Direct
Footnotes: F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RARE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +31,400
Change %
Price: $0.000000
Shares after: 31,400
Date: 01 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,400
Exercise price: $53.69
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date

Footnote F2

Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric.

Footnote F3

Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.

Footnote F4

Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

Footnote F5

Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Footnote F6

On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.